Quince Therapeutics (NASDAQ:QNCX) Posts Quarterly Earnings Results, Misses Expectations By $0.09 EPS

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) issued its earnings results on Monday. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.09), Zacks reports. The firm had revenue of $0.17 million during the quarter.

Quince Therapeutics Stock Performance

Shares of Quince Therapeutics stock traded down $0.05 during trading hours on Friday, reaching $1.35. 47,716 shares of the stock traded hands, compared to its average volume of 244,789. The company has a 50 day moving average price of $1.47 and a 200 day moving average price of $1.45. Quince Therapeutics has a one year low of $0.51 and a one year high of $2.45. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $59.40 million, a price-to-earnings ratio of -1.09 and a beta of 0.71.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. D. Boral Capital dropped their price target on Quince Therapeutics from $12.00 to $4.00 and set a "buy" rating on the stock in a report on Tuesday. Brookline Capital Management assumed coverage on shares of Quince Therapeutics in a research note on Wednesday, December 18th. They issued a "buy" rating and a $9.00 price objective for the company. Finally, Oppenheimer began coverage on shares of Quince Therapeutics in a report on Monday, March 24th. They issued an "outperform" rating and a $10.00 price target on the stock. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $8.00.

Remove Ads

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.